Provided is the compound (3S)-3-[4-[[5-[(8-Methoxy-3,4-dihydro-2H-quinolin-1-yl)methyl]-2-thienyl]methoxy]phenyl]hex-4-ynoic acid. Further provided is a process for preparing the compound and an intermediate in this process. The compound is an agonist of GRP-40. The compound may be useful in the treatment of diabetes.